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Abstract
Background: As pharmacological therapies have largely failed so far, stem cell therapy has recently come into the focus of
ALS research. Neuroprotective potential was shown for several types of stem and progenitor cells, mainly due to release of
trophic factors. In the present study, we assessed the effects of intracerebroventricular injection of glucagon-like peptide 1
(GLP-1) releasing mesenchymal stromal cells (MSC) in mutant SOD1 (G93A) transgenic mice.
Methodology/Principal Findings: To improve the neuroprotective effects of native MSC, they had been transfected with a
plasmid vector encoding a GLP-1 fusion gene prior to the injection, as GLP-1 was shown to exhibit neuroprotective
properties before. Cells were encapsulated and therefore protected against rejection. After intracerebroventricular injection
of these GLP-1 MSC capsules in presymptomatic SOD1 (G93A) mice, we assessed possible protective effects by survival
analysis, measurement of body weight, daily monitoring and evaluation of motor performance by rotarod and footprint
analyses. Motor neuron numbers in the spinal cord as well as the amount of astrocytosis, microglial activation, heat shock
response and neuronal nitric oxide synthase (nNOS) expression were analyzed by immunohistological methods. Treatment
with GLP-1 producing MSC capsules significantly prolonged survival by 13 days, delayed symptom onset by 15 days and
weight loss by 14 days and led to significant improvements in motor performance tests compared to vehicle treated
controls. Histological data are mainly in favour of anti-inflammatory effects of GLP-1 producing MSC capsules with reduced
detection of inflammatory markers and a significant heat shock protein increase.
Conclusion/Significance: Intracerebroventricular injection of GLP-1 MSC capsules shows neuroprotective potential in the
SOD1 (G93A) mouse model.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative
disorder which causes death of motor neurons in the cortex, brain
stem and spinal cord. Patients develop rapidly progressive paralysis
and muscle wasting and ultimately die due to respiratory
insufficiency within 3–5 years after diagnosis [1]. Aproximately
10% of ALS cases are familial (fALS). About 20% of these fALS
cases are linked to mutations in the gene coding for superoxide
dismutase 1 (SOD1) [2]. In a transgenic mouse model expressing a
mutant form of SOD1 carrying the Gly93 R Ala substitution,
progressive death of motor neurons occurs in the ventral horn
region of the lumbar spinal cord and the mice develop a
phenotype similar to ALS [3].
So far, only the glutamate antagonist riluzole has shown
marginal neuroprotective potential in the treatment of amyotro-
phic lateral sclerosis (ALS) [4]. Therefore, current efforts focus on
experimental therapies. Recent studies have demonstrated that
stem cell transplantation presents a novel therapeutic approach for
a variety of neurological diseases (for review see [5]). Current
attempts to establish cell therapy in ALS mainly focus on the
generation of a more protective environment for degenerating
motor neurons rather than on cell replacement. Genetic modifi-
cation of transplanted cells aiming to increase the production of
trophic factors is feasible and enhances the benefit of native cells
[6–8]. The use of a single drug targeting only one out of many
interacting pathomechanisms in ALS has proven to be of little or
no effect in a large number of previous studies. Therapeutic
approaches which combine several mechanisms of action appear
more promising.
In this context, glucagon-like peptide 1 (GLP-1) is an interesting
candidate for the treatment of neurodegenerative disorders. GLP-
1 is an intestinal peptide, stimulating glucose-dependent insulin
secretion after food intake and thereby leading to reduction of
blood glucose levels [9,10]. GLP-1 and its receptor can be found in
pancreatic b cells, intestinal cells but also in the brain [11,12].
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capacities [13] and is neuroprotective against excitotoxicity in vitro
and in vivo [14,15]. While GLP-1 penetrates the blood brain
barrier, its short half life prevents systemic administration [16,17].
This led to the development of GLP-1 analogues with increased
half life such as exendin 4 or liraglutide [18–20] for subcutaneous
injection. Several studies showed therapeutic potential of these
GLP-1 agonists in animal models of neurodegenerative diseases
such as Alzheimer’s disease [21], Parkinson’s disease [22],
Huntington’s disease [23] and also after experimental traumatic
brain injury [24]. In a study in SOD1 (G93A) mice, exendin 4 did
not prolong survival or slow down disease progression of the mice,
but led to amelioration of motor neuron [25].
One major advantage of intracerebroventricular implantation
of a vehicle releasing GLP-1–as opposed to daily injections of
GLP-1 analogues is that it warrants continuous release of the
neurotrophic factor. Another method to assure continuous growth
factor delivery would be the use of osmotic minipumps which must
be replaced every few weeks. Encapsulated cells instead of mini
pumps allow the abandonment of catheters which reduces the risk
of complications and requires only one surgical procedure that was
shown several times to be feasible in humans before [26,27].
Encapsulated cell biodelivery has been suggested as a novel
approach in cellular therapy to deliver therapeutic substances like
GLP-1 in a sustainable fashion. Encapsulation in a biopolymer
material allows the use of non-autologous cells as it prevents any
host versus graft reaction [28].
In our study, we investigated an encapsulated mesenchymal
stromal cell (MSC) line, which has been modified to produce GLP-
1. Neuroprotective effects of these GLP-1 producing MSC
capsules have already been shown in experimental traumatic
brain injury and in a transgenic Alzheimer’s disease model
[21,24]. The rationale to use these genetically modified MSC was
to combine the genuine neuroprotective potential of adult stem
cells together with their ability to serve as a vehicle for continuous
release of a trophic factor. In a mouse model of Alzheimer’s’
disease, is has already been established that the neurotrophic
effects of native mesenchymal cells can be potentiated by increased
GLP-1 production [8].
We administered GLP-1 MSC capsules to transgenic SOD1
(G93A) mice via intracerebroventricular injection before disease
onset (day 40). By monitoring of survival, motor function, weight
and general condition and by additional histological analyses, we
could provide evidence for their neuroprotective potential in the
ALS mouse model.
Results
Survival Study
General condition. Disease onset was defined by daily
assessment of the general condition of the mice. Animals treated
with GLP-1 MSC showed a slighter deterioration compared to
vehicle controls (figure 1B). The shift in symptom onset was
15 days on average. Differences to controls were significant
between day 110 and 120 (Two-way ANOVA, p,0.01 and
p,0.001).
Survival. Survival times of animals treated with GLP-1 MSC
were significantly prolonged as compared to vehicle-treated mice
(figure 1A) (Gehan-Breslow-Wilcoxon test, p,0.05). On average,
GLP-1 MSC- treated animals lived 13 days longer than the
controls (130d vs. 117d).
Weight. Treatment with GLP-1 MSC led to a significant
delay of weight loss (figure 1C). While vehicle treated controls
started to lose weight already at week 14, GLP-1 MSC- treated
animals gained weight until week 15. Significant differences to
controls were measured for two weeks (week 16 & 17, two-way
ANOVA, p,0.05 & p,0.01).
Rotarod. Rotarod performance of vehicle treated controls
started to decrease at week 13, while performance of GLP-1 MSC-
treated animals was not altered before week 16 (figure 2A). For
two weeks the deterioration of motor performance was signifi-
cantly less in the GLP-1 MSC group (week 16 & 17, two-way
ANOVA, p,0.001).
Footprint analyses – step length. First decrease in step
length occurred at week 14 in vehicle treated controls; therefore 3
weeks earlier than in GLP-1 MSC- treated mice (figure 2B).
Differences between both groups were significant from week 16 to
week 18 (Two-way ANOVA, p,0.001).
Footprint analyses – runtime. While runtime along the
footprint track started to increase not before week 18 in the GLP-1
MSC- treated group, vehicle treated controls already showed an
increase at week 15 (figure 2C). From week 17 to week 18 these
differences became significant (Two-way ANOVA, p,0.01 &
p,0.001).
Histological Analyses
Brain sections of 6 vehicle and 6 GLP-1 MSC- treated mice
were studied by GFAP staining. We found a glial scar above the
right ventricle in five of 12 animals (figure 3). Capsules within the
ventricles or in surrounding tissue were not detectable as most
likely the capsules remained in the ventricles and were washed out
during perfusion of animals prior to paraffin embedding. Enlarged
ventricles were not observed.
Motor neuron numbers were not significantly altered between
vehicle- and GLP-1 MSC- treated groups as shown by cresyl violet
staining (figure 4A). Treatment with GLP-1 MSC led to a
reduction of astrocytosis as detected by GFAP (glial fibrillary acidic
protein) staining in lumbar spinal cord sections compared to
vehicle treated controls even though quantitative analysis was not
statistically significant (figure 4B). Similarly, microgliosis as
measured by Iba1 (ionized calcium binding adaptor molecule 1)
immunostaining was reduced in GLP-1 MSC- treated animals
(figure 4C). Staining for anti-HSP70 (heat shock protein 70)
revealed a significantly increased heat shock response in GLP-1
MSC- treated mice compared to controls (unpaired t-test, p,0.05)
(figure 4D). nNOS (neuronal nitric oxide synthase) immunolabel-
ling was slightly decreased in the GLP-1 MSC- treated animals
(figure 4E).
Even though counting of motor neuron cell bodies in cresyl
violet stained spinal cord sections did not result in apparent
differences between GLP-1 MSC and vehicle-treated animals,
staining for mictrotubule-associated protein 2 (MAP2) as a
neuronal marker shower more intense labelling, namely of
neuronal processes in spinal cord sections of GLP-1 MSC- treated
animals (figure 5).
Discussion
Cellular therapy is currently being investigated as a novel
therapeutic option for the treatment of ALS, mainly with the aim
to provide a neuroprotective environment and trophic support for
degenerating motor neurons. Mesenchymal stem cells (MSC)
present good candidates for this approach as they are easily
available, highly proliferative and barely immunogenic [29]. A
previous study assessed the effect of intraspinal injection of MSC in
an ALS rodent model: the authors showed moderate improve-
ments in motor function and survival which were attributed to
anti-inflammatory and neurotrophic effects of MSC [30]. One
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ALS could be that motor neuron degeneration is widespread along
the spinal cord, brain and brainstem [1]. As cells do barely migrate
following injection into brain or spinal cord parenchyma, local
administration may therefore not be sufficient to delay disease
progression over a long period. Other studies have evaluated the
benefit of intravenous administration of mesenchymal cells in ALS
mouse models and could show that cells migrated some distance
away from blood vessels to the gray and white matter of brain and
spinal cord [31,32]. But intravenous administration holds the risk
of cell loss during circulation due to settling of infused cells in
many peripheral tissues, such as lung, liver or spleen [32,33], and
moreover requires high numbers of cells.
As opposed to local intraspinal or intravenous administration,
intracerebroventricular injection has the advantage that neuro-
protective factors released by the cells can directly reach the whole
spinal cord and brain via the cerebrospinal fluid (CSF), reducing
the risk of adverse effects and the number of cells required. This is
a major advantage for future translation into clinical trials. It is not
necessary to make the cells enter the spinal cord directly because
trophic factors can be distributed via the CSF. This assumption is
confirmed by a study of Zhang et al. who showed limited
migration of intrathecally administered human MSC in the spinal
cord parenchyma of ALS mice but nevertheless significant
neuroprotection [34].
There is evidence that MSC cause direct trophic effects without
further differentiation into new phenotypes, probably due to
release of trophic factors such as VEGF and BDNF [35,36]. To
further enhance the effects of native stem cells, they can be
genetically engineered to produce neuroprotective proteins. This
approach was tested before in studies using genetically modified
GDNF-releasing MSC in a rat model of ALS: The protective
effects of native MSC on motor neuron survival, preservation of
motor endplates and survival and motor function of animals were
improved by GDNF producing MSC [7]. Encapsulation is a
promising approach to reduce the risks and complications
associated with cellular therapies in the central nervous system:
In a first phase I clinical trial in ALS to assess safety and
tolerability of encapsulated genetically engineered baby hamster
kidney (BHK) cells releasing human ciliary neurotrophic factor
(CNTF), therapeutic levels of the secreted peptide could be
detected for several weeks without limiting side effects [37]. A
phase I/II clinical trial confirmed the safety and tolerability of
intrathecal implants of these cell capsules, with signs of only a very
mild humoral immune response [38]. Studies in experimental
animal models using the same cell capsules as in the present study
showed complete prevention of any immune response by
microencapsulation of cells prior to transplantation [21,24]. Use
of encapsulated cells may further be considered as a safety measure
against tissue damage which occurred in a study assessing
intraspinal transplantation of non-encapsulated cells in a model
Figure 1. Effects of GLP-1 treatment on survival times, general condition and weight measurements. Presymptomatic GLP-1 treatment
(GLP-1 MSC) prolonged survival (A) and improved general condition (B) compared to vehicle controls (vehicle). GLP-1 treated animals gained weight
for a longer period than vehicle controls (C). Data are mean 6 SEM of 8 (5R/3=) (control) and 10 (6R/4=) (GLP-1) treated animals. (A) Kaplan-Meyer
Curve, followed by Gehan-Breslow-Wilcoxon test. (B & C) two-way ANOVA, followed by Bonferroni post-test. (**) p,0.01; (***) p,0.001.
doi:10.1371/journal.pone.0036857.g001
Figure 2. Effects of GLP-1 treatment on rotarod performance and footprint analyses. Presymptomatic GLP-1 treatment (GLP-1 MSC)
improved rotarod performance (A), step length (B) and runtime (C) compared to vehicle controls (vehicle). Data are mean 6 SEM of 8 (5R/3=)
(control) and 10 (6R/4=) (GLP-1) treated animals. Two-way ANOVA, followed by Bonferroni post-test. (*) p,0.05; (**) p,0.01; (***) p,0.001.
doi:10.1371/journal.pone.0036857.g002
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and caused collagen depositions and subsequent local tissue
damage [39]. Our post mortem analysis of brain sections after
intracerebroventricular injection of encapsulated MSC showed
only minor glial scars along the injection channel in part of the
animals but no further abnormalities such as enlargement of the
ventricles. This indicates safety and tolerability of the implantation
technique. In the present study, the intestinal peptide GLP-1 was
used to increase the therapeutic capacity of MSC, based on several
studies showing neuroprotective effects of a stimulation of GLP-1
receptors which are present in the mammalian brain
[14,21,24,40]. While analogues of GLP-1, like exendin 4 or
liraglutide, showed neuroprotective potential in models of
Alzheimer’s [20] and Parkinson’s disease [19,41], the effect in
ALS mice so far has been insufficient. Exendin 4 treatment via
subcutaneous pumps protected motor neurons and reduced GFAP
and caspase 3 amount in spinal cord tissue of SOD1 mice, but
disease progression and survival of the animals were not affected
[25].
We decided to use GLP-1 releasing MSC to combine the
protective effects of adult stem cells and continuous growth factor
delivery into the CSF. The commercial availability of well
characterized GMP manufactured GLP-1 producing MSC allows
fast translation to clinical trials in case of a positive outcome in
preclinical studies. Previous studies with GLP-1 releasing Cell-
BeadsH, have confirmed steady GLP-1 production at a rate of
2.85–3.68 fmol/capsule/h after intracerebroventricular injection.
Further it was shown that GLP-1 reaches the affected regions by
circulation within the CSF after intracerebroventricular injection
in cats [40] and rats [24] by measurement of the CSF
concentrations of GLP-1. These studies have also proven steady
GLP-1-release of CellBeadsH after explantation and a cell viability
of at least 95%, independent from the time interval between cell
implantation and analysis [24]. Based on these results, we
conclude that the beneficial effects of intracerebroventricular
injection of GLP-1 producing MSC capsules in SOD1 (G93A)
mice resulted at least in parts from increased GLP-1 concentra-
tions in the CSF. Treatment with GLP-1 releasing MSC
significantly increased lifespan and improved motor function of
SOD1 (G93A) mice. Even though motor neuron loss as assessed
by cresyl violet staining and counting of motor neuron cell bodies
was not significantly different between vehicle- and GLP-1 MSC-
treated groups, we found a stronger signal of MAP2 staining after
GLP-1 treatment. One of the earliest events in mutant SOD1 mice
is impaired axonal transport [42,43]. Increased staining for could
indicate preservation of neuronal processes, resulting in increased
functional capacity of remaining motor neurons due to preserved
integrity of microtubules and axonal transport. Further experi-
ments should include analysis of neuromuscular end plates to
clarify whether GLP-1 MSC have an effect on terminal motor
axons. Besides a direct effect on motor neurons, positive effects on
the disease course may be explained by an anti-inflammatory
mechanism of action of GLP-1-releasing MSC. Increased astro-
cytosis and microglial activation are hallmarks of the disease [44]
and is now well recognized that SOD1 (G93A) glial cells
contribute to motor neuron death in ALS [45,46]. Intracerebro-
ventricular injection of GLP-1 releasing MSC led to a (not
significant) reduction of astrocytosis and to a significant increase of
the heat shock response, suggesting less functional impairment of
remaining astrocytes. Increased levels of HSP were already shown
to be neuroprotective [47] and the HSP-inducing drug arimoclo-
mol slowed down disease progression and increased survival in
ALS mice [48]. This is in line with the reduced microglial
activation and nNOS immunostaining after GLP-1 MSC injec-
tion. Similar to astrocytes, unaffected microglia provide trophic
support but activation leads to increased release of neurotoxic
factors such as nitric oxide [49,50]. Reduced microglial activation
therefore may lead to reduced levels of nitric oxide and therefore
have contributed to the better outcome of GLP-1 MSC-treated
mice.
Figure 3. Analysis of post mortem brain tissue at day 110 of SOD1 (G93A) mice. In 5 of 12 animals there was a glial scar visible above the
right ventricle as it was shown by GFAP staining. Rectangle in the left picture is showed enlarged on the right side. Scale bar 500 mm.
doi:10.1371/journal.pone.0036857.g003
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PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e36857In our pilot study we could demonstrate the feasibility of
intracerebroventricular injection of encapsulated GLP-1 produc-
ing MSC in ALS mice. Our results regarding motor performance
and survival of the animals as well as the observed effects on
inflammatory markers in the spinal cord strongly suggest further
evaluation of the potential of encapsulated MSC therapy for
treatment of ALS.
Material and Methods
Ethics Statement
All experiments were carried out in strict accordance with the
internationally accepted principles in the care and use of
experimental animals and were approved by the Institutional
Animal Care and Research Advisory Committee at Hanover
Medical School and permitted by the Lower Saxonian State Office
for Consumer Protection and Food Safety regional (Permit
Number: AZ 07/1324).
Animals
G93A transgenic familial ALS mice (high copy number;
B6SJLTg (SOD1-G93A)1Gur/J) [3] were obtained from The
Jackson Laboratory (Bar Harbor, ME, USA). These mice over-
express the human mutant SOD1 allele containing the Gly93 R
Ala (G93A) substitution. We maintained the transgenic G93A
hemizygotes by mating transgenic males with B6SJLF1/J hybrid
females. Transgenic offspring was genotyped by PCR assay of
DNA obtained from tail tissue. Mice were housed under controlled
conditions (12:12 light:dark cycle) with free access to food and
water. Animals of the same sex were kept in groups of up to five
animals in Makrolon cages type II (UNO, Zevenaar, Netherlands).
Males were kept solitary in the same cage type only when they
were also used for breeding.
Alginate Microcapsules
A human, bone marrow-derived, single cell derived mesenchy-
mal stromal cell line provided by CellMed AG, Alzenau, Germany
as previously described [21] was used in this study. It was
immortalized by transduction with the human Telomerase
Reverse Transcriptase (hTERT) gene [51]. After transfection with
a plasmid vector encoding a GLP-1 fusion gene, the cells produced
an 8.7 kDa dimeric GLP-1 molecule. The cells are embedded in a
spherical shaped alginate matrix (about 160 mm in diameter,
figure 6). The alginate matrix is generated by cross-linking alginate
with barium ions. Each capsule (trademark CellBeadsH) contained
about 94 cells. Until use, the cell capsules were stored in liquid
nitrogen.
Preoperative Procedure
For surgery animals were anesthetized by a combination of
ketamine (0.1 ml/100 g, 100mg/kg), xylazine (0.01 ml/100g,
2 mg/kg) and midazolame (0.05 ml/100 g, 0.5 mg/kg), prepared
under sterile conditions with 0.9% sodium chloride. Appropriate
to the body weight (0.1 ml/10 g) anaesthesia was administered
intraperitoneally. Duration of anaesthesia was up to 60 minutes,
which was sufficient for the surgery. Depth of anaesthesia was
controlled by the toe-and eyelid- reflex.
Cerebroventricular Injection
The heads of the animals were shaved and disinfected. Eye
ointment protected the eyes against dehydration. The head was
fixed with ear bars in a stereotactic frame and the skin was
disclosed longitudinally. Bregma was visualized by 30% hydro-
gen peroxide and coordinates of bregma were recorded. From
bregma injection coordinates (1 mm lateral, 0.5 mm anterior)
were adjusted before the cranial bone was enclosed under visual
control with a drill head of 1.4 mm diameter. Following the
preparation of injection position, 100 ml of the cell solution was
dropped on a glass dish and up to 30 GLP-1 MSC capsules
were taken with a 10 ml Hamilton syringe under visual control.
Thy syringe filled with GLP-1 MSC capsules was kept upright
until usage so the beads were concentrated in the top of the tip.
After adjustment of injection coordinates, the syringe was
inserted 5 mm into the brain, and then withdrawn 1 mm so
the cells were injected 4 mm distal from the cranial bone. 1 ml
cell solution was injected all at once. After a waiting period of
Figure 4. Immunohistological analysis of spinal cord tissue at day 110 of SOD1 (G93A) mice. (A) Motor neuron loss was not ameliorated
by GLP-1 treatment (GLP-1 MSC) compared to vehicle treated controls (vehicle). (B) Astrocytosis (C) and microglial activation were marginally less in
GLP-1 treated animals compared to controls. (D) Heat shock response was significantly increased by GLP-1 treatment and nNOS (E) was reduced
slightly in these animals. Unpaired t-test. (*) p,0.05. Scale bar 100 mm.
doi:10.1371/journal.pone.0036857.g004
Figure 5. Immunhistological analysis of MAP2 in spinal cord tissue of SOD1 (G93A) mice. Staining against microtubule associated protein
2 was stronger in animals treated with GLP-1 (GLP-1 MSC) compared to vehicle treated controls (vehicle). Scale bar 100 mm.
doi:10.1371/journal.pone.0036857.g005
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0.9% sodium chloride under visual control. Remaining cell
capsules were counted and recorded in the surgery protocol.
Postoperative Procedure
Following wound closure animals received a single dose of
carprofene (5 mg/kg subcutaneously) and metamizole via
drinking water (200 mg/kg/day) for 3 postoperative days for
analgesia.
Treatment Groups
Mice were treated with either GLP-1 producing MSC
capsules or empty alginate capsules as vehicle control (control:
n=10 (6R/4=); GLP-1 MSC: n=8 (5R/3=) for assessment of
survival and motor performance; control: n=6 (5R/1=); GLP-1
MSC: n=6 (5R/1=) for histological analyses). An increase in
the therapeutic effect of encapsulated GLP-1 producing MSC
capsules as compared to native encapsulated MSC has already
been proven before [24]. To reduce the total number of
animals in the study, we therefore did not include a second
control group of mice injected with alginate beads filled with
native MSC. Animals of each litter were randomly attributed to
either the GLP-1 MSC group or the control group and were
monitored until they reached disease end stage. The cerebro-
ventricular injection of either GLP-1 producing or empty
capsules was administered once at a presymptomatic disease
stage (d40). After surgery, experimenters were blinded to
treatment groups so that animals were objectively monitored
throughout the whole period of behavioural assessment.
Behavioural Assessment
General condition. For weekly assessment of general condi-
tion from week 14 we used a behavioural score system as
previously described [52,53], based on the score developed by
Vercelli et al. [30] from 1 to 5 defined as follows:
Figure 6. Alginate encapsulated GLP-1 producing mesenchymal cells. (A) Encapsulation with alginate leads to GLP-1 MSC capsules with a
mean diameter of 161 mm. (B) GLP-1, oxygen and nutrients are able to pass the alginate barrier, but the cells are protected against the hosts’ immune
system.
doi:10.1371/journal.pone.0036857.g006
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2. slight signs of destabilized gait and paralysis of the hind limbs,
3. obvious paralysis and destabilized gait
4. fully developed paralysis of the hind limbs, animals only crawl
on the forelimbs
5. fully developed paralysis of the hind limbs, animals predom-
inantly lie on the side and/or are not able to straighten up after
turning them on the back or lost more than 20% of their
starting weight.
When animals reached a score of 2, macerated food was given
daily for easy access to food and hydration. Reaching a score of 1,
the animals were euthanized.
Evaluation of onset and survival. Day of onset was set as
the first day the animals reached a score of 4 in the daily
behavioural assessment. Animals were killed when they reached a
score of 1 and this age (in days) was recorded as survival time.
Weight. We recorded the weight of the animals weekly,
beginning at 10 weeks of age, using a normal digital balance
ranging up to 800 g in 0.1 g steps.
Rotarod. Beginning at 11 weeks of age, we analyzed motor
function using a rotarod apparatus from IITC (IITC Life Science
Inc. California). After an adaptation period of 5 days the test was
performed weekly. Mice had to remain on the rotating cylinders
for up to 180 s with an increasing speed up to 18 rpm. Rotarod
test was performed as previously described [52].
Footprint analyses. Footprint analyses for step length and
runtime were performed weekly starting the same week as rotarod
tests performance [52]. The hind feet were dipped into black
finger print and animals were placed on a gangway covered with
conventional masking tape. Footprints were analyzed with respect
to the step length using the FOOTPRINTS software (Version 1.22
by K. Klapdor and B. Dulfer [54]). In addition, the time animals
needed to run along the track (50 cm) was measured.
2.4 Histological Evaluation
At d110, six vehicle and six GLP-1 MSC-treated animals (5R/
1=) were sacrificed by an overdose of anesthetic (ketamine
(0.1 ml/100 g, 100 mg/kg), rompune (0.01 ml/100 g, 2 mg/kg)
and midazolame (0.05 ml/100 g, 0.5 mg/kg)). After transcardial
perfusion with 25 ml 4% paraformaldehyde (PFA) in phosphate
buffer (PBS), the brain and lumbar part of the spinal cord was
removed. Postfixation for 1 day in 4% PFA was followed by
storage in 70% ethanol until dehydration by progressively more
concentrated ethanol baths and xylene (Mallinckrodt Baker B.V.,
Deventer, Netherlands) and embedding in paraffin blocks.
Sections of 7 mm were cut on a microtome and 5–6 sections were
transferred to one object slide, respectively.
2.4.1 Motor neuron survival. One slide per animal (i.e. 5–6
spinal cord sections) was rehydrated in xylene and graded ethanol,
stained with 0.2% Thionin, dehydrated in graded ethanol and
xylene and coverslipped with Eukitt quick hardening mounting
medium (Sigma-Aldrich, Steinheim, Germany). At 20x magnifi-
cation in an Olympus B661 microscope, cells in the ventral horn
region with a diameter .200 mm
2 were defined as motor neurons,
according to Chen et al., who determined a- motor neurons as
cells with cell body areas ranging from 200 to 1100 mm
2 [55].
Motor neurons were counted, using cell* software (Olympus,
Hamburg, Germany). Only intact ventral horn regions were used
for counting so that, depending on the quality of the section, 5 to
12 ventral horn regions were counted for motor neuron numbers
and the mean was used for statistical evaluation.
2.4.2 Immunohistochemistry. For immunohistochemical
staining, slides were rehydrated in xylene, graded ethanol and
PBS. For antigen retrieval, slides were boiled for 5–10 min in
citrate buffer and cooled for 15 minutes at 4uC. After immersion
in PBS, slides were blocked for 5 min with peroxidase block
(DakoCytomation, Glostrup, Denmark) and antibody diluent
(DakoCytomation, Glostrup, Denmark) for 1 h followed by
overnight incubation at 4uC with primary antibodies specific for
GFAP (1:600; polyclonal rabbit anti glial fibrillary acidic protein;
DakoCytomation, Glostrup, Denmark), Iba1 (1:250; polyclonal
rabbit anti ionized calcium binding adaptor molecule 1; WAKO
Chemicals GmbH, Neuss, Germany), HSP70 (1:250; monoclonal
mouse anti heat shock protein; Acris antibodies, Herford,
Germany) or nNOS (1:250; polyclonal rabbit anti neuronal nitric
oxide synthase; Millipore, Bedford, USA) diluted in antibody
diluent. Secondary HRP antibody anti-rabbit or anti-mouse
respectively (EnVision+System-HRP (AEC+); DakoCytomation,
Glostrup, Denmark) was added for 30 min, followed by 20–
25 min incubation in chromogene substrate (EnVision+System-
HRP (AEC); Dako-Cytomation, Glostrup, Denmark). Slides were
covered with Kaiser’s glycerol gelatin (Merck, Darmstadt,
Germany).
For quantitative analyses of astrocytosis, microglial activation,
heat shock response and nNOS staining, the percentage of stained
area of the ventral horn was determined using the phase analysis
tool of cell* software in pictures taken at 20x magnification by an
Olympus Bx61 microscope.
For MAP2 staining, slides were blocked with 5% goat serum in
PBS with 0.3% Triton X-100 (Sigma-Aldrich, Steinheim,
Germany) for 1 h followed by overnight incubation at 4uC with
primary antibodies specific for MAP2 (1:250; polyclonal rabbit
anti microtubule-associated protein 2; Millipore, Bedford, USA)
diluted in 5% goat serum in PBS with 0.3% Triton X-100.
Secondary anti-rabbit or Alexa Fluor 488 antibody (1:500; anti-
IgG (H+L); Invitrogen, Darmstadt, Germany) was added for
45 min. Slides were then counterstained with the fluorescent DNA
dye DAPI (10 mg/ml; Invitrogen, Darmstadt, Germany).
Statistics. Data were analyzed by two-way ANOVA in order
to evaluate time evolution of the different parameters. In case of
significant parameter interaction (p,0.05), comparison with a
Bonferroni posthoc test was performed. All data are presented as
mean 6 SD and significance level was set as p,0.05. Survival was
analyzed by the Gehan- Breslow- Wilcoxon test with a significance
level of p,0.05.
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